
The European Commission gave its blessing on Friday, September 4, to the Italian government’s plan to pump €199.45 million (US$236.12 million) into Alitalia, as Rome continues to throw money at its embattled flag-carrying airline, reported Euractiv.
The €200 million grant is intended to compensate Alitalia for damages incurred by the coronavirus pandemic, and EU competition regulators stated the bailout is in line with Union law.
According to the Commission, the money “will compensate the damage suffered by Alitalia that is directly linked to the coronavirus outbreak” and “does not exceed what is necessary to make good the damage.”
EU law allows governments to pump cash into struggling companies that suffer “damage directly caused by exceptional occurrences.” In a statement, the EU executive reiterated that the virus outbreak qualifies as “exceptional.”
A report by an Italian parliament committee had found that Alitalia incurred damages worth around €250 million between February and June, although the government aid takes into account the March-June period.
“This measure will enable Italy to compensate Alitalia for the damage directly suffered due to the travel restrictions necessary to limit the spread of the coronavirus,” said Competition Commissioner Margrethe Vestager in a statement.
Full Content: EurActive
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas